key: cord-0308215-hzlkjaqe
authors: Vlahos, Alexander E.; Talior-Volodarsky, Ilana; Kinney, Sean M.; Sefton, Michael V.
title: A scalable device-less biomaterial approach for subcutaneous islet transplantation
date: 2020-06-26
journal: bioRxiv
DOI: 10.1101/2020.06.26.172148
sha: b0fbaed1e560be5edbef1506470831fa508747bd
doc_id: 308215
cord_uid: hzlkjaqe

The subcutaneous space has been shown to be a suitable site for islet transplantation, however an abundance of islets is required to achieve normoglycemia, often requiring multiple donors. The loss of islets is due to the hypoxic conditions islets experience during revascularization, resulting in apoptosis. Therefore, to reduce the therapeutic dosage required to achieve normoglycemia, pre-vascularization of the subcutaneous space has been pursued. In this study, we highlight a biomaterial-based approach using a methacrylic acid copolymer coating to generate a robust pre-vascularized subcutaneous cavity for islet transplantation. We also devised a simple, but not-trivial, procedure for filling the cavity with an islet suspension in collagen. We show that the pre-vascularized site can support a marginal mass of islets to rapidly return streptozotocin-induced diabetic SCID/bg mice to normoglycemia. Furthermore, immunocompetent Sprague Daley rats remained normoglycemia for up to 70 days until they experienced graft destabilization as they outgrew their implants. This work highlights methacrylic acid-based biomaterials as a suitable pre-vascularization strategy for the subcutaneous space that is scalable and doesn’t require exogenous cells or growth factors. Summary In this study methacrylic acid copolymer coated tubes generated a robust vascular response in the subcutaneous space, which was critical to support islet transplantation in a streptozotocin-induced diabetic mouse model. More importantly, the subcutaneous pre-vascularization approach using this copolymer coating was scalable into a larger allogeneic rat model and returned animals to normoglycemia for up to 70 days. This platform highlights the potential of a scalable biomaterial approach for pre-vascularization of the subcutaneous space in larger animal models.

Therapeutic polymers such as methacrylic acid (MAA)-based biomaterials generate 86 vessels when subcutaneously transplanted in a variety of different mouse models (CD1 10,11 , 87 SCID/bg 3 and C57BL6 12 ), without the use of exogenous growth factors or cells. In a separate 88 study, we showed that in coating a polypropylene mesh chamber with this copolymer 12 , we 89 could restore diabetic C56Bl/6 mice to normoglycemia with syngeneic islets 13 ; uncoated mesh 90 chambers were ineffective in this model.

In this study, we adapted a method used by Pepper et al 2 . A silicone catheter was 92 coated with a copolymer of MAA and isodecyl acrylate (IDA) and used to pre-vascularized the 93 subcutaneous space in SCID/bg mice and Sprague Dawley (SD) rats. Following pre-94 vascularization, the catheter was removed, and pancreatic islets were delivered into the pre-95 vascularized cavity (Fig. 1) . First, we determined when the MAA-coated tubes generated the 96 maximal number of vessels after subcutaneously implanted in immune-compromised SCID/bg 97 mice. We confirmed that the pre-vascularized site could support the engraftment of a marginal 98 dosage of pancreatic islets. Finally, we showed that this MAA-based approach could be scaled 99 up into a larger rat model and support the long-term engraftment of allogeneic islets in 100 immunosuppressed recipients. This study highlights the potential of using a biomaterial-based 101 approach to pre-vascularize the subcutaneous space for islet transplantation, with emphasis on 102 its ability to be scaled up into larger animal models. 137 SCID/bg mice were made diabetic using a single i.p. injection of streptozotocin (180 138 mg/kg, Sigma Aldrich) one week before islet transplantation (Supplementary Figure 1A) .

Sprague Daley rats were made diabetic using a single i.v. injection of streptozotocin (40 mg/kg) 140 via the tail vein one week before islet transplantation. Animals were monitored daily (OneTouch 141 UltraStar2) and only animals with non-fasting blood glucose levels above 20 mM for two 142 consecutive days were used for transplantation studies.

Prior to transplantation, the pancreatic islets were washed three times with PBS and 144 then mixed with neutralized Type I collagen (3.0 mg/mL -PureCol, Advanced Biomatrix).

Depending on the recipient species, different numbers of IEQs were mixed with various volumes 146 of collagen as outlined in Table 1 

which was used as a guide to inject the islet/collagen mixture into the pre-vascularized site. The

larger tube was partly removed during the injection (Fig. 1) . Following the injection, both tubes 162 were removed, and the incision was then sutured using PolysorbTM 3-0 sutures (Covidien).

Age-matched mice were used as no pre-vascularization controls, delivering the islet/collagen 164 mixture (with HUVEC) using the PE90 tubing into the unmodified subcutaneous space.

Xenogeneic islet transplantations into the SCID/bg mouse did not require any intra-islet vessels. The average vessel density was highest in the grafts retrieved from the MAA-249 coated tube group (105 ± 15 vessels/mm 2 ), which was significantly higher than the unmodified 250 SQ space group (54 ± 11 vessels/mm 2 ). This value was also higher than the uncoated silicone 251 tube group (60 ± 10 vessels/mm 2 ) but this was not significant (Supplementary Figure 2B) . 

The majority of rats in this study had their grafts assessed for up to 21 days, but some 283 Surprisingly, animals from each of the three groups responded to a glucose bolus when 284 challenged with an OGTT at day 14, returning to normoglycemia within 120 minutes post-285 administration (Fig. 5D ). There were no significant differences among the three groups in 286 response to the glucose bolus (Fig. 5E ).

Similar to the SCID/bg mice, retrieving the grafts for histological analysis was more 288 challenging than anticipated. Islet grafts from the unmodified subcutaneous group did not have 289 any insulin positive staining, consistent with the poor functional outcome observed on 290 normalizing blood glucose levels. At day 21, we were able to retrieve 4 of 8 grafts from animals 291 within the MAA-coated pre-vascularization group. Grafts that were retrieved at day 21 showed 292 extensive insulin staining with intact pancreatic islets and intra-islet vasculature (Fig. 6B) . Both 293 intra-islet vessels and the vessels throughout the surrounding area were mature (CD31 + and 294 SMA + ). The average CD31 + vessel density of the explanted grafts (islet and surrounding tissue)

295 was 178 ± 8 vessels per mm 2 (Fig. 6C) . Grafts at day 90 were unable to be reliably retrieved 296 since they were completely integrated with the host's subcutaneous space. 

To reduce the therapeutic dose required to achieve normoglycemia in the subcutaneous 309 space, pre-vascularization is a suitable alternative where vessels are generated before islet 310 transplantation to provide the necessary oxygen and nutrients to support islet engraftment and 311 survival 5,7,9 . We hypothesized that a purely biomaterial-based approach for pre-vascularization 312 would be simpler to translate than an approach based on using cells to generate vessels 1 

Consistent with these results, we observed that uncoated silicone tubes generated many 324 vessels in the subcutaneous space of both mice and rats, presumably by generating a foreign 325 body response that was halted by removing the tube at day 14 (Fig. 2B, 4B) .

We followed a protocol similar to that used by Pepper 

there was a significant delay in the time it took to achieve normoglycemia (Fig. 3B) . Pancreatic 344 islets that survive the immediate hypoxic conditions secrete VEGF-A 22 to recruit neutrophils 23 345 and drive re-vascularization once transplanted, which may explain the delay observed in the no 346 pre-vascularization group relative to the groups with pre-vascularization (Fig. 3A, B) .

The benefits of MAA-driven pre-vascularization were most apparent in the larger SD rat 348 model (Fig. 5A) . MAA-coated tubes generated the greatest number of vessels (Fig. 4B) and

showed the most consistent return to normoglycemia (Fig. 5A) , compared to the less 350 vascularized site associated with the uncoated silicone tube group (Fig. 4B) . Due to the 351 avascular nature of the subcutaneous space, 4000 IEQ did not have any therapeutic effect 352 when transplanted into the unmodified subcutaneous space (Fig. 5A -red line) . Interestingly, 353 all groups could respond to an OGTT at day 14 (Fig. 5D) , suggesting that although islet grafts 354 could not regulate non-fasting blood glucose levels, some residual islet function remained 355 sufficient to respond in a glucose challenge test 24 .

The co-delivery of HUVEC with the islets in SCID/bg (but not the rat) may have also 357 contributed to generating a more robust vascularization response after transplantation into the 358 pre-vascularized site. In previous studies, the addition of HUVEC with islet collagen 359 microtissues generated a greater number of vessels at early time points and prevented collagen 360 degradation compared to grafts without HUVEC following subcutaneous islet transplantation 1 .

HUVEC were included to enable a comparison with these previous studies where 750 IEQ was 362 needed to restore normoglycemia without pre-vascularization. HUVEC help drive re-363 vascularization of transplanted pancreatic islets by secreting VEGF 25 (in addition to that 364 produced by islets) and other pro-angiogenic growth factors 26 . However, by co-delivering 365 HUVEC, the perceived therapeutic benefit of having more vessels before islet transplantation 366 ( Fig. 2A, B) may have been obscured.

Retrieval of the islet grafts was more challenging than anticipated in the SD rat model,

unlike what was seen in the SCID/bg mouse with or without 1 pre-vascularization. In the rat, 369 pancreatic islets were delivered within a collagen gel to support their engraftment and 370 function 27-29 , however collagen degrades over time when subcutaneously transplanted without 371 endothelial cells 1 . In our explants, we could only find intact islets (insulin + ) in implants that were harvested at day 21 in the MAA-coated tube group (Fig. 6B) . The area surrounding the 373 embedded islets was well vascularized (CD31 + and SMA + ), and the presence of intra-islet 374 vessels was also observed (Fig. 6B, C) . Explanted grafts from the uncoated tube or unmodified 375 subcutaneous groups could not be distinguished from the surrounding subcutaneous space.

There was little or no insulin staining in the explanted tissue and may be due to poor islet 377 survival, since the uncoated tube and unmodified subcutaneous space groups had significantly 378 higher non-fasting blood glucose levels compared to the MAA-coated tube group (Fig. 5A) .

At day 90, grafts had completely integrated with the host's tissue and could not be 380 distinguished from the surrounding subcutaneous space making retrievability not possible.

Although we did not directly confirm islet integration and re-vascularization using CLARITY as in 382 previous studies 1,4 , we expect that the vessel islet integration seen before 1 was critical for their 383 therapeutic efficacy. Long-term integration of the islet graft was possible because the collagen 384 delivery vehicle was remodeled, but this integration can make retrieval more difficult, unlike in the subcutaneous space but not islet transplants. In our study, we found a combination of 399 ALS, fingolimod and MMF was necessary to prevent rapid graft rejection (Fig. 5A) .

Tacrolimus is a calcineurin inhibitor, which inhibits T-cell function, but its 401 immunosuppressive effect can be variable and is dependent on its bioavailability 37 , 832  833  834  835  836  837  838  839  840  841  842  843  844  845  846 

Modular tissue engineering for the 474 vascularization of subcutaneously transplanted pancreatic islets

A prevascularized subcutaneous device-less site for islet and 477 cellular transplantation

Injectable and inherently 479 vascularizing semi-interpenetrating polymer network for delivering cells to the 480 subcutaneous space

Endothelialized collagen based pseudo-islets enables tuneable 482 subcutaneous diabetes therapy

Diabetes is reversed in a murine model by marginal mass 484 syngeneic islet transplantation using a subcutaneous cell pouch device

Engineering transferrable microvascular meshes for subcutaneous 487 islet transplantation

The Efficacy of a Prevascularized, Retrievable Poly(D,L,-lactide-489 co-ε-caprolactone) Subcutaneous Scaffold as Transplantation Site for Pancreatic 490

Harnessing the Foreign Body Reaction in Marginal Mass 492 Device-less Subcutaneous Islet Transplantation in Mice

Long-term allogeneic islet graft survival in prevascularized 495 subcutaneous sites without immunosuppressive treatment

Effect of methacrylic acid beads on 498 the sonic hedgehog signaling pathway and macrophage polarization in a 499 subcutaneous injection mouse model

The role of insulin growth 501 factor-1 on the vascular regenerative effect of MAA coated disks and macrophage-502 endothelial cell crosstalk

Methacrylic acid copolymer coating 504 enhances constructive remodeling of polypropylene mesh by increasing the 505 vascular response

Acid Copolymer Coating of 507 Polypropylene Mesh Chamber Improves Subcutaneous Islet Engraftment

The effect of methacrylic acid in smooth coatings on 509 dTHP1 and HUVEC gene expression

Vascularization of PLGA-based bio-artificial beds by hypoxia-511 preconditioned mesenchymal stem cells for subcutaneous xenogeneic islet 512 transplantation

An evolving new paradigm: 514 endothelial cells--conditional innate immune cells

Toxic effects of immunosuppressive drugs: 516 mechanisms and strategies for controlling them

Transplantation of human pancreatic endoderm cells reverses 518 diabetes post transplantation in a prevascularized subcutaneous site

MAA-coated tubes pre-vascularized the subcutaneous space of Sprague 682

A) The surrounding subcutaneous space of rats implanted with the MAA-coated 683 tube had significantly more CD31 + vessels compared to the uncoated tube

Representative histology images of the surrounding 685 subcutaneous space 14 days after an uncoated tube or a MAA-coated tube was inserted. Both 686 conditions had mature vessels in the surrounding subcutaneous area (arrows -CD31 + and 687 SMA + ). T = tubes

Figure 6: Pancreatic islets recovered from the pre-vascularized space created with the 730

Representative histological image of pancreatic islets at day 731 21 transplanted into the pre-vascularized space created by the MAA-coated tube. 700 μm scale 732 bar. The pancreatic islets were B) insulin + with both mature intra-islet and peripheral vessels 733 (CD31 + and SMA + ). Scale bars of main images = 200 μm and the scale bars of the insets = 50 734 μm. C) While only four of the eight grafts could be retrieved, the average number of CD31 + 735 vessels of the pancreatic islet grafts (islets + surrounding tissue

Supplementary Figure 1: Experimental setup of pre-vascularization and islet 761 transplantation experiments. A) SCID/bg mice were subcutaneously implanted with either an 762

At 764 time of transplantation (day 0), the tubes were removed, and islets embedded within a collagen 765 gel with HUVEC were implanted into the pre-vascularized site or an unmodified subcutaneous 766 space. Non-fasting blood glucose readings were checked daily and IPGTT was administered on 767 day 21. Normoglycemic animals were sacrificed at day 42 and their explants were assessed via 768 histology; unmodified animals were sacrificed at day 28. B) The implantation of the MAA

On the day of the allogeneic islet transplantation (after the initial 14 days), 772 animals were given a daily oral gavage with mycophenolic acid (20 mg/kg/day, that was tapered 773 down to 0 mg/kg between days 14 to 21) and fingolimod (2 mg/kg/day). Non-fasting blood 774 glucose readings were measured daily and an OGTT was administered on day 14 after islet 775 transplantation. On day 21, animals for the short-term studies were sacrificed, and their grafts 776 were assessed via histology. For long-term studies

Supplementary Figure 2: Pancreatic islets recovered from the pre-vascularized space of 796

A) Pancreatic islets delivered into the pre-vascularized subcutaneous space 797 were vascularized with intra-islet vessels (CD31 + within dotted line) and were intact

However, delivery into the unmodified subcutaneous space resulted in fragmented islets 799 that did not have intra-islet vessels clearly present (CD31 + ) at day 28. CD31 + vessels were 800 present throughout the collagen + EC grafts in all three groups

05). However, only 4 of 5 grafts in the MAA-804 coated group, 2 of 5 grafts in the uncoated silicone tube group could be reliably explanted from 805 the subcutaneous space. Average +/-SEM, n = 4 for MAA-coated group, n = 2 for uncoated 806 group